Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$75.21 USD

75.21
605,371

-1.55 (-2.02%)

Updated May 29, 2024 04:00 PM ET

After-Market: $75.26 +0.05 (0.07%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News

by Zacks Equity Research

Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

by Zacks Equity Research

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More

by Zacks Equity Research

Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

by Zacks Equity Research

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

Axsome (AXSM) Up 27.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More

by Zacks Equity Research

Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.

Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi

by Zacks Equity Research

Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.

Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus

by Zacks Equity Research

Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.

Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates

by Zacks Equity Research

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.

Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.

Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.

Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked

by Zacks Equity Research

Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.

Kinjel Shah headshot

Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More

by Kinjel Shah

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly above estimates.

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

by Zacks Equity Research

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.

Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.